NeoLumina Bioscience

What NeoLumina Bioscience does

NeoLumina Bioscience is a privately held biopharmaceutical company founded in 2018 that develops psychedelic-derived medicines for mental health conditions. The company's sole disclosed product candidate is PEX010, a psilocybin-based therapeutic in which the active metabolite psilocin is delivered through an advanced delivery system designed to enable precise dosing and improved therapeutic outcomes. PEX010 is being developed initially for the treatment of binge eating disorder, an indication the company characterizes as underserved within the psychedelic medicine space.

The company's core technology centers on a psilocin delivery formulation co-developed with Catalent, a global provider of advanced drug delivery technologies. The differentiation cited is the novel method of architecture for delivering psilocin, although no patents, proprietary molecular entities, or granted IP are documented in the available data. NeoLumina is preparing to seek FDA authorization to enter a Phase 2 clinical trial for PEX010 in binge eating disorder, situating the asset at the preclinical-to-Phase 2 transition.

NeoLumina is a pre-revenue, clinical-stage developer with no disclosed pricing, commercial distribution channels, marketing infrastructure, customers, headcount, management team, funding rounds, or geographic markets served. The intended revenue model is prescription pharmaceutical product sales following regulatory approval, but no commercial launch timeline, payer strategy, or pricing model has been disclosed. Customer targeting is described horizontally at the persona level (patients with treatment-resistant mental health conditions), with binge eating disorder as the primary use case. The current evidence base supports only a narrow, single-asset profile focused on one indication.

Name

NeoLumina Bioscience

Website

https://neoluminabio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

NeoLumina Bioscience is a pre-revenue, clinical-stage biopharmaceutical company developing PEX010, a psilocybin-based therapeutic targeting binge eating disorder, using a psilocin delivery system co-developed with Catalent.

Ownership category

akta.pro rank

Product category

Psychedelic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Psychedelic pharmaceuticals
• Psilocybin therapeutics
• Mental health treatment
• Binge eating disorder
• Drug delivery system

Headquarters

HQ city

Burnaby

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel

Revenue model

1. Pharmaceutical product sales: As a clinical-stage biotech company developing pharmaceutical products, NeoLumina's intended revenue model is through the sale of prescription therapeutic products following regulatory approval. The company is currently in pre-revenue clinical development stage.

Core offering

NeoLumina Bioscience develops psychedelic-based pharmaceutical products for mental health conditions. Its lead candidate, PEX010, is a psilocybin-based therapeutic being developed for the treatment of binge eating disorder, leveraging a novel psilocin delivery system co-developed with Catalent to enable precise dosing and improved therapeutic delivery.

Product overview

NeoLumina Bioscience is a pharmaceutical development company with a single lead product, PEX010, a psilocybin-based drug candidate. The company's primary focus is advancing PEX010 through clinical development, specifically preparing for FDA approval of a Phase 2 clinical trial for binge eating disorder. NeoLumina has partnered with Catalent to develop the psilocin delivery system for this product.

Differentiator

Problem solved

Functional benefit

Products and services

• PEX010

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• CatalentcoreStrategic or Co-development Partner · 7 November 2025NeoLumina has partnered with Catalent to develop a psilocin delivery system aimed at treating mental health disorders. This partnership represents a major strategic collaboration for NeoLumina's psychedelic medicine pipeline, leveraging Catalent's expertise in pharmaceutical delivery technologies. The collaboration is focused on developing an advanced delivery system for psilocin, the active metabolite of psilocybin, to enable precise dosing and improved therapeutic delivery of the company's PEX010 product candidate.

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• GH Research: Clinical-stage company developing mebufotenin and other psychedelic compounds for psychiatric and neurological disorders. Comparable to NeoLumina as a focused psychedelic-medicine developer pursuing CNS indications.
• Compass Pathways: Clinical-stage psychedelic-medicine company developing psilocybin-based therapy, primarily for treatment-resistant depression. Most directly comparable to NeoLumina given shared psilocybin-based pharmaceutical approach and CNS focus.
• Cybin: Clinical-stage psychedelic therapeutics company developing psilocybin-based and deuterated tryptamine candidates for mental health. Comparable in target indication space and psychedelic-pharmaceutical development model.
• MindMed: Public psychedelic-medicine company developing LSD and psilocybin-based therapies for mental health and addiction. Comparable to NeoLumina as a clinical-stage developer of psychedelic pharmaceuticals targeting CNS indications.
• Atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health, with a portfolio approach across multiple compounds and indications. Comparable to NeoLumina in psychedelic-medicine category and CNS focus.

Emerging players

• Field Trip Health: Operates psychedelic-assisted therapy clinics and develops novel psychedelic molecules. Comparable in the broader psychedelic-medicine ecosystem, though its clinical-services model differs from NeoLumina's pure pharmaceutical approach.
• Bright Minds Biosciences: Clinical-stage company developing next-generation serotonergic drugs for CNS disorders including epilepsy and depression. Comparable as a small-cap CNS-focused developer pursuing novel mechanisms of action.
• Silo Pharma: Early-stage developer of psychedelic and CNS-focused therapeutics, including psilocybin-based candidates. Comparable as a smaller, single-indication-focused psychedelic-medicine peer.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/neolumina-bioscience-inc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoLumina Bioscience